In particular, both generic companies and originator companies called for a single Community Patent and the creation of a unified and specialised patent judiciary in Europe.
Nii geneerilisi kui ka originaalravimeid tootvad ettevõtted pooldasid ühtset ühenduse patenti ning ühtse ja spetsialiseerunud patendikohtu loomist Euroopas.